Combination of aspartic acid and glutamic acid inhibits tumor cell proliferation

• Published in: Biomedical Research 2016/04/01, Vol.37(2), pp.153-159
• Main Authors: YAMAGUCHI, Yoshie, YAMAMOTO, Katsunori, SATO, Yoshinori, INOUE, Shinjiro, MORINAGA, Tetsuo, HIRANO, Eiichi
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Aspartic Acid - pharmacology; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glutamic Acid - pharmacology; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Placenta - chemistry; Placenta - metabolism; Pregnancy; Proto-Oncogene Proteins c-akt - metabolism; Rabbits; Signal Transduction - drug effects; Xenograft Model Antitumor Assays
• ISSN: 0388-6107; 1880-313X
• DOI: 10.2220/biomedres.37.153

Placental extract contains several biologically active compounds, and pharmacological induction of placental extract has therapeutic effects, such as improving liver function in patients with hepatitis or cirrhosis. Here, we searched for novel molecules with an anti-tumor activity in placental extracts. Active molecules were separated by chromatographic analysis, and their antiproliferative activities were determined by a colorimetric assay. We identified aspartic acid and glutamic acid to possess the antiproliferative activity against human hepatoma cells. Furthermore, we showed that the combination of aspartic acid and glutamic acid exhibited enhanced antiproliferative activity, and inhibited Akt phosphorylation. We also examined in vivo tumor inhibition activity using the rabbit VX2 liver tumor model. The treatment mixture (emulsion of the amino acids with Lipiodol) administered by hepatic artery injection inhibited tumor cell growth of the rabbit VX2 liver. These results suggest that the combination of aspartic acid and glutamic acid may be useful for induction of tumor cell death, and has the potential for clinical use as a cancer therapeutic agent.